IL7 and chronic myelogenous leukemia, BCR-ABL1 positive: Namely, BM-MSCs induce CML cell resistance to imatinib treatment-induced apoptosis by secreting interleukin-7 (IL-7) and activating the JAK1-STAT5 signaling.